公开(公告)号：US20190151298A1

公开(公告)日：2019-05-23

申请号：US16259134

申请日：2019-01-28

Applicant: Takeda Pharmaceutical Company Limited ,  Zinfandel Pharmaceuticals, Inc.

Inventor： Allen D. Roses ,  Rajneesh Taneja

IPC: A61K31/4439 ,  C07D417/12 ,  C12Q1/6883

Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.

公开(公告)号：US20190119225A1

公开(公告)日：2019-04-25

申请号：US16230634

申请日：2018-12-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro Banno ,  Masahiro Kamaura ,  Kazuaki Takami ,  Koichiro Fukuda ,  Shigekazu Sasaki

IPC: C07D263/46 ,  C07D213/70 ,  A61P27/02 ,  C07D239/34 ,  A61K31/421 ,  C07D213/65 ,  C07D263/38 ,  A61K31/415 ,  C07D231/22 ,  C07D231/12 ,  A61K31/505 ,  A61K31/4418

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US10226426B2

公开(公告)日：2019-03-12

申请号：US15554688

申请日：2016-03-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masatoshi Karashima ,  Katsuhiko Yamamoto ,  Takashi Kojima ,  Yukihiro Ikeda

IPC: A61K9/14 ,  A61K47/16 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/32 ,  A61K47/34 ,  A61K9/10 ,  A61K47/38 ,  A61K31/341 ,  A61K31/405 ,  A61K31/55 ,  A61K31/522 ,  A61K9/16

Abstract: The present invention provides a method of producing a suspension containing a nano-cocrystal having an average particle size of not more than 300 nm, a polymer having a number average molecular weight of not less than 3,000, a surfactant having a number average molecular weight of less than 3,000 and water, which method including wet grinding a cocrystal, which is constituted of an organic compound and a cocrystal former and is not dissociated by wet grinding, in water containing the polymer and the surfactant.

公开(公告)号：US10202376B2

公开(公告)日：2019-02-12

申请号：US15538297

申请日：2015-12-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Yuhei Miyanohana ,  Masaki Ogino ,  Yuta Tanaka ,  Makoto Fushimi ,  Tomohiro Okawa ,  Yuki Hanya ,  Tatsuki Koike

IPC: C07D471/04 ,  A61K31/437 ,  C07D487/04 ,  A61P25/00 ,  A61P29/00

Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

公开(公告)号：US20190000981A1

公开(公告)日：2019-01-03

申请号：US16064061

申请日：2016-12-21

Applicant: Nigel W. Bunnett ,  Christopher J.H. Porter ,  Derek Cole ,  Gareth Hicks ,  Junya Shirai ,  Gavin Hirst ,  Takeda Pharmaceutical Company Limited

Inventor： Nigel W. Bunnett ,  Christopher J.H. Porter ,  Derek Cole ,  Gareth Hicks ,  Junya Shirai ,  Gavin Hirst

IPC: A61K47/54 ,  A61K47/60 ,  A61K31/575 ,  A61K31/44 ,  A61P43/00

Abstract: The present invention relates to tripartite compounds comprising a modulator moiety for endosomal G protein-coupled receptors like neurokinin-1 receptor, a linker and a lipid anchor suitable for anchoring the tripartite compound into a plasma membrane. The present invention also relates to a prodrug and a pharmaceutical composition comprising the tripartite compound and the use of the tripartite compound for the treatment of a disease or disorder mediated by endosomal G protein-coupled receptors signalling like NK1R signalling.

公开(公告)号：US10093629B2

公开(公告)日：2018-10-09

申请号：US15321609

申请日：2015-06-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi Yamamoto ,  Junya Shirai ,  Tsuneo Oda ,  Mitsunori Kono ,  Atsuko Ochida ,  Takashi Imada ,  Hidekazu Tokuhara ,  Yoshihide Tomata ,  Naoki Ishii ,  Michiko Tawada ,  Yoshiyuki Fukase ,  Tomoya Yukawa ,  Shoji Fukumoto

IPC: C07D217/26 ,  C07D491/056 ,  C07D491/048 ,  C07F7/08 ,  C07D471/04 ,  A61K31/4375 ,  A61K31/472 ,  A61K31/4741 ,  C07D217/14 ,  C07D491/14

Abstract: Provided are heterocyclic compounds having a RORγt inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US10081624B2

公开(公告)日：2018-09-25

申请号：US15506380

申请日：2015-08-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Akira Kaieda ,  Naoki Ishii ,  Hiroshi Nara ,  Masato Yoshikawa ,  Masaki Daini ,  Masashi Toyofuku ,  Kousuke Hidaka

IPC: C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/08 ,  C07D513/04

CPC classification number: C07D413/12 ,  A61K31/4245 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/55 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/08 ,  C07D491/107 ,  C07D513/04

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US10077266B2

公开(公告)日：2018-09-18

申请号：US15621761

申请日：2017-06-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Jason W. Brown ,  Stephen Hitchcock ,  Maria Hopkins ,  Shota Kikuchi ,  Holger Monenschein ,  Holly Reichard ,  Kristin Schleicher ,  Huikai Sun ,  Todd Macklin

IPC: A61K31/4985 ,  C07D471/04

Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.

公开(公告)号：US10053468B2

公开(公告)日：2018-08-21

申请号：US14902309

申请日：2014-07-02

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Satoshi Yamamoto ,  Junya Shirai ,  Hiroyuki Watanabe ,  Shoji Fukumoto ,  Tsuneo Oda ,  Hidekazu Tokuhara ,  Yoshihide Tomata ,  Naoki Ishii ,  Michiko Tawada ,  Mitsunori Kono ,  Atsuko Ochida ,  Takashi Imada ,  Yoshiyuki Fukase ,  Tomoya Yukawa

IPC: C07D491/056 ,  C07D217/26 ,  C07D401/06 ,  C07D405/06 ,  C07D409/06 ,  C07D413/06 ,  C07D417/06 ,  C07D471/04 ,  C07D491/048 ,  C07D401/12 ,  C07D413/12 ,  C07D491/04 ,  C07D413/14 ,  C07D401/04 ,  C07D405/12 ,  C07F7/08

CPC classification number: C07D491/056 ,  C07D217/26 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D471/04 ,  C07D491/04 ,  C07D491/048 ,  C07F7/0812

Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. wherein each symbol is as defined in the specification.

公开(公告)号：US09963443B2

公开(公告)日：2018-05-08

申请号：US15316937

申请日：2015-06-08

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Shuhei Ikeda

IPC: A61K31/506 ,  C07D401/14 ,  A61K51/04 ,  C07D401/04 ,  C07D405/14 ,  C07D417/14

CPC classification number: C07D401/14 ,  A61K51/0455 ,  A61K51/0459 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/04 ,  C07D405/14 ,  C07D417/14

Abstract: The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of CH24H in mammals. The compound of the present invention is represented by the formula (I): wherein each symbol is as defined in the specification.